Jahandar Jahanipour

Jahandar Jahanipour

Auto-generated profile, based on publicly available information

Jahandar Jahanipour

National Institute of Neurological Disorders and Stroke, Flow and Imaging Cytometry Core Facility, Bethesda, MD, United States

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 March 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
DMDragan Maric
Dragan Maric
JJJahandar Jahanipour
Jahandar Jahanipour
XLXiaoyang Rebecca Li
Xiaoyang Rebecca Li
ASAditi Singh
Aditi Singh
AMAryan Mobiny
Aryan Mobiny
BRBadrinath Roysam
Badrinath Roysam
Mapping biological processes in brain tissues requires piecing together numerous histological observations of multiple tissue samples. We present a direct method that generates readouts for a comprehensive panel of biomarkers from serial whole-brain slices, characterizing all major brain cell types, at scales ranging from subcellular compartments, individual cells, local multi-cellular niches, to whole-brain regions from each slice. We use iterative cycles of optimized 10-plex immunostaining with 10-color epifluorescence imaging to accumulate highly enriched image datasets from individual whole-brain slices, from which seamless signal-corrected mosaics are reconstructed. Specific fluorescent signals of interest are isolated computationally, rejecting autofluorescence, imaging noise, cross-channel bleed-through, and cross-labeling. Reliable large-scale cell detection and segmentation are achieved using deep neural networks. Cell phenotyping is performed by analyzing unique biomarker combinations over appropriate subcellular compartments. This approach can accelerate pre-clinical drug evaluation and system-level brain histology studies by simultaneously profiling multiple biological processes in their native anatomical context.

20 December 2018 in The Analyst
Verified
Journal Article
Closed access
PDF file
SBSebastian Berisha
Sebastian Berisha
MLMahsa Lotfollahi
Mahsa Lotfollahi
JJJahandar Jahanipour
Jahandar Jahanipour
IGIlker Gurcan
Ilker Gurcan
MWMichael Walsh
Michael Walsh
DMDavid Mayerich
David Mayerich
Current methods for cancer detection rely on tissue biopsy, chemical labeling/staining, and examination of the tissue by a pathologist. Though these methods continue to remain the gold standard, they are non-quantitative and susceptible to human error. Fourier transform infrared (FTIR) spectroscopic imaging has shown potential as a quantitative alternative to traditional histology. However, identification of histological components requires reliable classification based on molecular spectra, which are susceptible to artifacts introduced by noise and scattering. Several tissue types, particularly in heterogeneous tissue regions, tend to confound traditional classification methods. Convolutional neural networks (CNNs) are the current state-of-the-art in image classification, providing the ability to learn spatial characteristics of images. In this paper, we demonstrate that CNNs with architectures designed to process both spectral and spatial information can significantly improve classifier performance over per-pixel spectral classification. We report classification results after applying CNNs to data from tissue microarrays (TMAs) to identify six major cellular and acellular constituents of tissue, namely adipocytes, blood, collagen, epithelium, necrosis, and myofibroblasts. Experimental results show that the use of spatial information in addition to the spectral information brings significant improvements in the classifier performance and allows classification of cellular subtypes, such as adipocytes, that exhibit minimal chemical information but have distinct spatial characteristics. This work demonstrates the application and efficiency of deep learning algorithms in improving the diagnostic techniques in clinical and research activities related to cancer.

30 November 2022 in Brain Communications
Verified
Journal Article
Open access
PDF file
AKAlexander Ksendzovsky
Alexander Ksendzovsky
MBMuznabanu Bachani
Muznabanu Bachani
MAMarcelle Altshuler
Marcelle Altshuler
SWStuart Walbridge
Stuart Walbridge
AMArmin Mortazavi
Armin Mortazavi
KZKareem A Zaghloul
Kareem A Zaghloul
Recent studies suggest that changes in neuronal metabolism are associated with epilepsy. High rates of ATP depletion, lactate dehydrogenase A and lactate production have all been found in epilepsy patients, animal and tissue culture models. As such, it can be hypothesized that chronic seizures lead to continuing elevations in neuronal energy demand which may lead to an adapted metabolic response and elevations of lactate dehydrogenase A. In this study, we examine elevations in the lactate dehydrogenase A protein as a long-term cellular adaptation to elevated metabolic demand from chronic neuronal activation. We investigate this cellular adaptation in human tissue samples and explore the mechanisms of lactate dehydrogenase A upregulation using cultured neurons treated with low Mg2+, a manipulation that leads to NMDA-mediated neuronal activation. We demonstrate that human epileptic tissue preferentially upregulates neuronal lactate dehydrogenase A, and that in neuronal cultures chronic and repeated elevations in neural activity lead to upregulation of neuronal lactate dehydrogenase A. Similar to states of hypoxia, this metabolic change occurs through the AMP-activated protein kinase/hypoxia-inducible factor-1α pathway. Our data therefore reveal a novel long-term bioenergetic adaptation that occurs in chronically activated neurons and provide a basis for understanding the interplay between metabolism and neural activity during epilepsy.

30 April 2024 in Pain
Verified
Journal Article
Closed access
MSMatthew R. Sapio
Matthew R. Sapio
ESEllen S. Staedtler
Ellen S. Staedtler
DKDiana M. King
Diana M. King
DMDragan Maric
Dragan Maric
JJJahandar Jahanipour
Jahandar Jahanipour
MImichael iadarola
michael iadarola
Adenosine receptors are a family of purinergic G protein–coupled receptors that are widely distributed in bodily organs and in the peripheral and central nervous systems. Recently, antihyperalgesic actions have been suggested for the adenosine A3 receptor, and its agonists have been proposed as new neuropathic pain treatments. We hypothesized that these receptors may be expressed in nociceptive primary afferent neurons. However, RNA sequencing across species, eg, rat, mouse, dog, and human, suggests that dorsal root ganglion (DRG) expression of ADORA3 is inconsistent. In rat and mouse, Adora3 shows very weak to no expression in DRG, whereas it is well expressed in human DRG. However, the cell types in human DRG that express ADORA3 have not been delineated. An examination of DRG cell types using in situ hybridization clearly detected ADORA3 transcripts in peripheral macrophages that are in close apposition to the neuronal perikarya but not in peripheral sensory neurons. By contrast, ADORA1 was found primarily in neurons, where it is broadly expressed at low levels. These results suggest that a more complex or indirect mechanism involving modulation of macrophage and/or microglial cells may underlie the potential analgesic action of adenosine A3 receptor agonism.

21 May 2023 in medRxiv
Verified
Preprint
Open access
PDF file
CRChristopher E. Ramsden
Christopher E. Ramsden
DZDaisy Zamora
Daisy Zamora
MHMark Horowitz
Mark Horowitz
JJJahandar Jahanipour
Jahandar Jahanipour
GKGregory S. Keyes
Gregory S. Keyes
DMDragan Maric
Dragan Maric
BACKGROUND: Sporadic Alzheimer’s disease (sAD) is not a global brain disease. Specific regions, layers and neurons degenerate early while others remain untouched even in advanced disease. The prevailing model used to explain this selective neurodegeneration—prion-like Tau spread—has key limitations and is not easily integrated with other defining sAD features. Instead, we propose that in humans Tau hyperphosphorylation occurs locally via disruption in ApoER2-Dab1 signaling and thus the presence of ApoER2 in neuronal membranes confers vulnerability to degeneration. Further, we propose that disruption of the Reelin/ApoE/ApoJ-ApoER2-Dab1 P85α-LIMK1-Tau-PSD95 (RAAAD-P-LTP) pathway induces deficits in memory and cognition by impeding neuronal lipoprotein internalization and destabilizing actin, microtubules, and synapses. This new model is based in part on our recent finding that ApoER2-Dab1 disruption is evident in entorhinal-hippocampal terminal zones in sAD. Here, we hypothesized that neurons that degenerate in the earliest stages of sAD (1) strongly express ApoER2 and (2) show evidence of ApoER2-Dab1 disruption through co-accumulation of multiple RAAAD-P-LTP components. METHODS: We applied in situ hybridization and immunohistochemistry to characterize ApoER2 expression and accumulation of RAAAD-P-LTP components in five regions that are prone to early pTau pathology in 64 rapidly autopsied cases spanning the clinicopathological spectrum of sAD. RESULTS: We found that: (1) selectively vulnerable neuron populations strongly express ApoER2; (2) numerous RAAAD P-LTP pathway components accumulate in neuritic plaques and abnormal neurons; and (3) RAAAD-P-LTP components were higher in MCI and sAD cases and correlated with histological progression and cognitive deficits. Multiplex-IHC revealed that Dab1, pP85α Tyr607 , pLIMK1 Thr508 , pTau and pPSD95 Thr19 accumulated together within dystrophic dendrites and soma of ApoER2-expressing neurons in the vicinity of ApoE/ApoJ enriched extracellular plaques. These observations provide evidence for molecular derangements that can be traced back to ApoER2-Dab1 disruption, in each of the sampled regions, layers, and neuron populations that are prone to early pTau pathology. CONCLUSION: Findings support the RAAAD-P-LTP hypothesis, a unifying model that implicates dendritic ApoER2-Dab1 disruption as the major driver of both pTau accumulation and neurodegeneration in sAD. This model provides a new conceptual framework to explain why specific neurons degenerate and identifies RAAAD-P-LTP pathway components as potential mechanism-based biomarkers and therapeutic targets for sAD.

6 July 2021 in medRxiv
Verified
Preprint
Open access
PDF file
CRChristopher E. Ramsden
Christopher E. Ramsden
GKGregory S. Keyes
Gregory S. Keyes
ECElizabeth Calzada
Elizabeth Calzada
MHMark Horowitz
Mark Horowitz
DZDaisy Zamora
Daisy Zamora
DMDragan Maric
Dragan Maric
Structured Background: Sporadic Alzheimer’s disease (sAD) lacks a unifying hypothesis that can account for the lipid peroxidation observed early in the disease, enrichment of ApoE in the central core of neuritic plaques, the hallmark plaques and tangles, and the selective vulnerability of entorhinal-hippocampal structures. Objective: We hypothesized that (1) high expression of ApoER2 (receptor for ApoE and Reelin) could help explain the selective anatomical vulnerability; and (2) lipid peroxidation of ApoE and ApoER2 contributes to sAD pathogenesis, by disrupting ApoE delivery and Reelin-ApoER2 signaling cascades. Methods: We conducted in vitro biochemical experiments, single-marker immunohistochemistry (IHC), and multiplex fluorescence-IHC (MP-IHC) in postmortem specimens from 26 individuals who died cognitively normal, with Mild Cognitive Impairment or with sAD. Results: In biochemical experiments, Lys- and His-enriched peptides within the binding domains of ApoE and ApoER2 and their corresponding recombinant proteins, were susceptible to attack by reactive lipid aldehydes, generating lipid-protein adducts and crosslinked ApoE-ApoER2 complexes. Using in situ hybridization alongside IHC and MP-IHC, we observed that: (1) ApoER2 is strongly expressed in terminal zones of the entorhinal-hippocampal ‘perforant path’ projections that underlie memory; (2) ApoE and lipid aldehyde-modified ApoE, Reelin, ApoER2 and several downstream components of Reelin-ApoER2 signaling cascades accumulated in the immediate vicinity of neuritic plaques in perforant path terminal zones in sAD cases; and (3) several ApoE/Reelin-ApoER2 pathway markers—including the ApoER2 ligand binding domain, Disabled homolog-1 (Dab1), and Thr19-phosphorylated PSD95 (marker of synaptic disassembly)—were higher in sAD cases than controls and positively correlated with histological progression and cognitive deficits. Conclusion: Results provide proof-of-concept that ApoE and ApoER2 are vulnerable to lipid aldehyde induced adduction and crosslinking and demonstrate derangements in multiple ApoE/Reelin-ApoER2-Dab1 axis components in perforant path terminal zones in AD. Findings provide the foundation for a unifying hypothesis implicating lipid peroxidation of ApoE particles and ApoE receptors in sAD in humans.